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Abstract
Clinical resistance to the second-generation antiandrogen enzalutamide in castration resistant 
prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights 
the unmet medical need for next generation antagonists. We have identified and characterized 
tetra-aryl cyclobutanes (CBs) as a new class of competitive AR antagonists that exhibit a unique 
mechanism of action. These CBs are structurally distinct from current antiandrogens 
(hydroxyflutamide, bicalutamide, and enzalutamide), and inhibit AR-mediated gene expression, 
cell proliferation, and tumor growth in several models of CRPC. Conformational profiling revealed 
that CBs stabilize an AR conformation resembling an unliganded receptor. Using a variety of 
techniques, it was determined that the AR:CB complex was not recruited to AR-regulated 
promoters and, like apo AR, remains sequestered in the cytoplasm bound to heat shock proteins. 
Thus, we have identified third generation AR antagonists whose unique mechanism of action 
suggests that they may have therapeutic potential in CRPC.
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Introduction
Prostate cancer is the most commonly diagnosed cancer among males in the United States, 
with more than 29,000 men estimated to die from this disease in 20141. The critical driver of 
prostate tumor progression is the androgen receptor (AR), and when the cancer has 
progressed past definitive local therapy, therapeutic strategies that target testicular androgen 
production (LH-RH agonists)2,3 or competitively inhibit androgen binding to the receptor 
(AR antagonists) are employed4. The suppression of AR function by anti-endocrine 
therapies is initially effective, but most tumors develop resistance, resulting in a more 
aggressive cancer known as castration-resistant prostate cancer (CRPC)5. CRPC typically 
exhibits sustained AR signaling through overexpression of the wild type AR6, upregulation 
of intratumoral androgen production7, alternative mRNA splicing resulting in truncated 
constitutively active AR variants8–10, or mutations within AR that result in altered receptor 
pharmacology11. Recent sequencing of advanced prostate cancers revealed that 44% of 
CRPCs had genomic alterations involving AR, with 20% containing an AR point 
mutation12. Mutations in the ligand-binding domain of AR often result in its ability to 
recognize antiandrogens as agonists. For example, the most common AR mutations, T877A 
and W741C, enable the first generation AR antagonists, flutamide (OHF) and bicalutamide 
(Bic), respectively, to function as agonists13,14. The second generation antiandrogens 
enzalutamide (Enz) and ARN-509 were developed to retain antagonist activity in the setting 
of acquired resistance, where AR mutations and/or overexpression are the most frequently 
observed15,16. Despite the impressive clinical activity of these contemporary antiandrogens, 
recent studies have revealed the emergence of acquired resistance which has been linked in 
part to a novel F876L mutation within the ligand-binding domain17,18. The discovery of this 
mutation, which negates the antagonist activity of enzalutamide and enables it to exhibit 
agonist activity, highlights the need to develop next-generation AR antagonists that are 
capable of targeting the broadest spectrum of resistance-conferring receptor mutations.
Herein, we describe the discovery and exploration of a tetra-aryl cyclobutane (CB) scaffold 
as a core building block for the development of next-generation antiandrogens. These tetra-
aryl cyclobutane compounds are structurally distinct antiandrogens, act as competitive 
inhibitors of AR, and obstruct androgen-mediated gene transcription in multiple models of 
hormone-refractory disease, including those in which mutant ARs (F876L, T877A, and 
W741C) and wild type AR overexpression are apparent. Importantly, the most potent 
antagonist of this class does not promote AR nuclear translocation and inhibits the growth of 
enzalutamide-resistant xenograft tumors.
Results
Cyclobutane (CB)-core ligands are AR antagonists
In an effort to identify inhibitors that overcome enzalutamide resistance, we utilized a CV1 
transient transfection system (MMTV-Luciferase reporter gene) expressing AR-F876L to 
screen an in-house library containing unique small-molecule scaffolds. After eliminating 
compounds with unsatisfactory toxicity profiles, the tetra-aryl cyclobutane (CB) compound 
1 emerged as a promising lead (Supplementary Results, Supplementary Table 1), providing 
effective inhibition of AR-F876L activity without general cellular toxicity, with an IC50 of 
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1.64 μM. Based upon this finding, an expanded library of cyclobutanes, appended with a 
variety of substituted arenes, was synthesized using an efficient and, in some cases, 
regioselective solid-state photodimerization approach19,20.
As above, the inhibitory activity of the CBs was measured using a CV1 transient transfection 
system in which AR-F876L was expressed. Substitution of the methoxy group on 1 with 
larger alkoxy groups (2-5), along with removal of the substitution on the pyrimidine ring (6) 
abolished antagonist activity. However, replacement with a methyl or ethyl group (7 and 8, 
respectively) retained activity. Although the tetra-chloro 9 was not potent, the presence of 
two-chloro substituents exhibited strong antagonist activity (10 and 11). Indeed, at sub-
micromolar concentrations, 10 was shown to completely inhibit the activity of AR-F876L. 
Addition of the methyl group on 12 retained activity. The exchange of the phenyl group with 
a diphenyl ring (13) or a thienyl group (14 and 17) was not well tolerated while substitution 
of the chloro with a methoxy group (15 and 16) retained activity. Additionally, thioether, 
sulfonyl, and amino substitutions were not effective (18-20).
To assess the therapeutic potential of the CBs, we examined their activity in cellular assays 
that model different mechanisms by which antiandrogen resistance occurs. To this end, we 
utilized the CV1 transient transfection assay to evaluate the antagonistic activity of the CBs 
against wt-AR and two additional mutants, T877A and W741C, associated with treatment 
failure in patients treated with OHF or Bic, respectively (Supplementary Table 1). The most 
potent inhibitors of AR-F876L (1, 7, 10, 11, 12, 15) were equally effective inhibitors of AR-
T877A and AR-W741C. Surprisingly, we observed that the potency of the CBs was right 
shifted when evaluated in the context of wt-AR as opposed to the mutants, with only 10 and 
15 having IC50 values less than 10 μM. The serendipitous discovery of mutant-selective 
antagonists suggests that it is possible to develop drugs that spare wt-AR activity. Such 
drugs may have particular utility in the treatment of late stage disease where cachexia is 
present and inhibition of wt-AR in muscle (or in the skeleton) is an undesirable activity.
CBs are competitive antagonists of wt and mutant AR forms
Because the structure of the CBs is markedly different from that of earlier generation AR 
ligands, we set out to define the biochemical basis for their inhibitory activity. Using 3H-
R1881 whole-cell competition binding assays, it was determined that all of the compounds 
tested inhibited agonist binding (Fig. 1a–d), with unlabeled 1, 10, and 15 effectively 
competing with R1881 (synthetic AR agonist) for binding to wt-AR and each mutant AR at 
concentrations near their predicted IC50 values (Supplementary Table 2). 10 demonstrated 
the highest potency against all AR variants. Consequently, we confirmed that 10 functions as 
a competitive antagonist of AR by Schild analysis, wherein increasing concentrations of 
compound did not decrease the maximal R1881-stimulated response of the MMTV 
luciferase reporter gene but did increase the apparent EC50 for R1881 in CV1 cells 
expressing wt-AR or AR-F876L (Supplementary Fig. 1). In addition, the selectivity of 10 
was confirmed by assessing its activity on other nuclear receptors (Supplementary Table 3).
Next we investigated whether 10 could antagonize endogenous AR transcriptional activity in 
the LNCaP prostate cancer cell line, which expresses AR-T877A. As shown in Fig. 2a, 10 
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inhibited R1881-dependent expression of KLK3 (also known as PSA), NKX3-1, and FKBP5 
mRNA with the same efficacy as enzalutamide. In addition, 10 inhibited androgen-
stimulated proliferation of LNCaP cells with similar efficacy to enzalutamide (Fig. 2b). To 
examine the therapeutic potential of the CBs, we generated two prostate cancer cell lines 
that model resistance mechanisms apparent in patients with CRPC: LNCaP-AR expressing a 
high level of AR and LNCaP-F876L expressing the AR mutant that is resistant to 
enzalutamide. In both cell lines, R1881 induces cell proliferation (Supplementary Fig. 2). 
We then examined the effectiveness of 1, 10, and 15 in inhibiting AR transcriptional activity 
in these CRPC cell lines.
As shown in Fig. 2c, Bic functioned as a partial agonist in the LNCaP-AR model, inducing 
substantial AR target gene expression likely accounting for the ineffectiveness of Bic in 
CRPC21. Similar to enzalutamide, the CBs did not promote AR target gene transcription in 
the LNCaP-AR cells. In the presence of R1881, 10 and 15 reversed androgen-stimulated 
gene expression, as did enzalutamide (Fig. 2d). However, 1 was less potent in this context 
likely reflecting its higher IC50 for wt-AR. As expected, enzalutamide stimulated rather than 
inhibited the expression of AR target genes in the LNCaP-F876L cell line. When analyzed 
in the same manner, the CBs maintained their antagonist activity (Fig. 2e). In addition, when 
the transcriptional activity of this mutant was analyzed in the presence of R1881, the CBs 
inhibited gene expression while, as expected, enzalutamide was ineffective (Fig. 2f). Direct 
quantification of R1881-mediated target gene expression and subsequent 10 inhibition is 
illustrated for a subset of genes (KLK3, NKX-1, and FKBP5) in Supplementary Fig. 3. In 
addition to LNCaP cells, we observed that 10 also inhibited androgen-stimulated expression 
of KLK3, NKX3-1, and FKBP5 mRNAs in LAPC4 and VCAP cells, well-established 
models of prostate cancer in which wt-AR is expressed (Supplementary Fig. 4).
CBs stabilize an apo-like conformation in AR
Previously, we showed that the pharmacological activity of AR ligands is primarily 
determined by their impact on receptor conformation and consequent coregulator 
recruitment22. This relationship was established using a cell-based conformation-profiling 
tool that uses coregulator-derived peptides to survey ligand-dependent presentation of 
protein-protein interaction surfaces as a proxy for receptor structure. This well-validated 
technology has been used to identify, classify, and accurately predict the biological activity 
of novel AR agonists and antagonists23. Using a variant of this tool optimized to study 
antagonist pharmacology, we performed a comparative analysis of the impact of benchmark 
ligands and 1, 10, and 15 on AR structure in intact cells (Fig. 3a). Analysis of the interaction 
data revealed similar cofactor interaction profiles for agonists (R1881, DeHT) and partial 
agonists (S4)24. The antagonists cyproterone acetate (CPA) and RU 486 induce similar 
conformational changes in receptor structure. As expected, enzalutamide and its related 
analogs, ARN509 and NC716, induce a unique AR conformation but, importantly, are not 
distinguishable from one another. These compounds show efficacy in certain models of 
CRPC15,16. Interestingly, the AR antagonists that fail to demonstrate efficacy in CRPC 
(nilutamide, flutamide, and bicalutamide) also cluster together, revealing common features 
in their mechanism of action. Importantly, the cofactor binding profiles of 1, 10, and 15 are 
most similar to the unliganded receptor (vehicle) and distinct from that of any other AR-
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ligand complex, a result which confirms their unique mechanism of action. The similarity of 
10-bound AR to unliganded receptor was confirmed by repeating a selection of cofactors, 
RN28S1 and HLA-B, in the presence of R1881 at the concentration of 10 utilized in the 
profiling experiment (Supplementary Fig. 5).
CBs block recruitment of AR to target gene promoters
To further discern the mechanisms underlying the unique activity of the CBs, we performed 
chromatin immunoprecipitation (ChIP) assays in both LNCaP-AR (Fig. 3b) and LNCaP-
F876L (Fig. 3c) cells and compared the ability of selected compounds to recruit AR to the 
regulatory regions of the androgen-regulated KLK3 and NKX3-1 genes. In the LNCaP-AR 
cells, Bic and R1881 facilitated AR recruitment to DNA, whereas enzalutamide and 10 were 
without effect (Fig. 3b). In the LNCaP-F876L model, however, enzalutamide promoted the 
binding of AR to DNA while 10 remained effective as an inhibitor of AR-DNA binding; 10 
inhibited AR recruitment more effectively than Bic (Fig. 3c). Thus, the unique changes in 
AR conformation noted above translate into a useful pharmacological activity.
CBs prevent androgen-mediated AR nuclear translocation
The observation that 10-bound AR adopts an apo-like conformation and disrupts AR-DNA 
interactions suggested that the 10-receptor complex might be sequestered in the cytoplasm. 
Thus, we used high content imaging (Cellomics ArrayScan) to perform unbiased 
quantification of AR subcellular distribution when complexed with 10, enzalutamide, and/or 
R1881. As expected, we observed an increase in AR nuclear-to-cytoplasmic (N/C) ratio 
upon addition of the agonist R1881 in VCaP prostate cancer cells as well as in HEK293 
cells expressing wt-AR (Fig. 4a). Enzalutamide treatment, in the absence and presence of 
R1881, was also found to increase the AR N/C ratio; this observation was somewhat 
surprising given that previous studies have shown that enzalutamide blocks nuclear 
translocation of the receptor16. Conversely, treatment with 10 did not promote AR nuclear 
localization, even upon cotreatment of cells with R1881 (Fig. 4a). Representative images 
from the VCaP analysis are shown in Fig. 4b. To further validate the ability of 10 to block 
androgen-mediated nuclear AR translocation, we performed subcellular fractionation 
experiments in HEK293 cells expressing wt-AR. Consistent with the imaging experiments, 
treatment of cells with R1881 resulted in the movement of AR from the cytoplasmic to 
nuclear fraction. Cotreatment of cells with 10 and R1881 demonstrated that 10, unlike 
enzalutamide, completely abrogated androgen-mediated accumulation of nuclear AR (Fig. 
4c). When assessed by high content imaging, treatment of HEK293 cells expressing AR-
F876L with 10 also resulted in inhibition of androgen-mediated nuclear accumulation 
(Supplementary Fig. 6). As expected, enzalutamide treatment resulted in a robust increase in 
AR N/C ratio in this model. Despite differential localization of AR, 10 does not promote AR 
degradation (Supplementary Fig. 7a–b).
It has been established that unliganded AR is located in the cytoplasm as part of a large 
multiprotein complex including heat shock proteins HSP90 and HSP7025,26. Upon androgen 
binding, a conformational change in the receptor results in loss of HSP90 binding, exposes a 
nuclear localization signal (NLS) within the receptor, and facilitates nuclear import. Given 
that the AR- 10 complex resembles unliganded receptor and is thus retained in the 
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cytoplasm, we set out to determine the impact of 10 binding on the interaction of AR with 
HSP90. We performed co-immunoprecipitation experiments with androgen-, 10-, or 
enzalutamide-bound AR and assessed the ability of the different complexes to interact with 
HSP90. R1881- and enzalutamide-bound AR were found to displace HSP90 from the 
receptor while 10-bound receptor maintained its interaction with HSP90, similar to apo-AR 
(Fig. 4d). Taken together, these data highlight a unique mechanism of action for the 
antagonist activity of 10 whereby as a result of its inability to displace HSP90 from AR, the 
receptor remains in the cytoplasm.
10 inhibits proliferation in cellular models of CRPC
To explore the impact of CBs on prostate cancer cell growth, we assessed the effects of 10 
on the growth of AR-overexpressing prostate cancer cells (LNCaP-AR) and in cells that are 
resistant to enzalutamide (LNCaP-F876L). As expected, Bic promoted cellular proliferation 
in AR overexpressing cells; however, enzalutamide and 10 were without effect (Fig. 5a). 
Similarly, in the enzalutamide-resistant cells, enzalutamide, but not 10 or Bic, promoted 
cellulars proliferation (Fig. 5b). Furthermore, 10 was able to inhibit R1881-mediated 
proliferation of AR-expressing VCaP cells, but not the growth of AR-negative cell lines PC3 
or DU145 (Supplementary Fig. 8a–c). These results highlight an important selective 
phenotypic consequence of the unique differences exhibited by 10 in the studies outlined 
above.
10 suppresses tumor growth in animal models of CRPC
Given the effect of 10 on the growth of CRPC cells, we proceeded to evaluate its activity in 
relevant xenograft models of prostate cancer. The initial studies were performed in intact 
male mice bearing LNCaP xenografts where the activity of enzalutamide (15 mpk) or 
escalating doses of 10 (5 to 100 mpk) were evaluated. Of note, 15 mg/kg enzalutamide, 
experimentally determined to be the MTD for this antiandrogen in NSG mice when 
administered i.p., was sufficient to inhibit AR activation in both tumor and endogenous 
tissues. In this study it was noted that administration of 10 (50 or 100 mpk) significantly 
inhibited androgen-responsive LNCaP prostate cancer tumor growth (Supplementary Fig. 9). 
To further evaluate the therapeutic potential of 10, we generated a mouse model in which 
enzalutamide-resistant AR-F876L cells were propagated as xenografts. For this study, 
castrated male mice bearing AR-F876L xenografts were treated with vehicle, enzalutamide 
(15 mpk), or escalating doses of 10 (30 to 100 mpk). As expected, these tumors grew in the 
absence of androgens (vehicle), and enzalutamide treatment failed to inhibit tumor 
growth18,21. Notably, treatment with 10 (50 or 100 mpk) completely suppressed (p < 0.0001) 
tumor growth for the entire 28-day treatment period (Fig. 5c), with the higher dose showing 
a trend towards tumor regression. Although the dose of 10 was higher than what was used 
for enzalutamide, we did not observe any changes in the behavior or health of the animals 
with even the highest dose of 10 treatment. Analysis of 10 drug levels (Supplementary Fig. 
10a) in plasma 24 hours after final treatment showed that the 50 (0.9±0.44 μM) and 100 
mg/kg (1.25±0.74 μM) doses were sufficient to inhibit AR F876L activity based on the 10 
transcriptional IC50 value reported in Supplementary Table 1. Furthermore, a single dose 
pharmacokinetic study (100 mg/kg) performed in F876L tumor-bearing mice revealed that 
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drug levels of 10 in the tumor ranged from 31.3 μM (1.5 hr post treatment) to 1.1 μM (24 hr 
post treatment), concentrations that are not toxic to prostate cancer cells in vitro 
(Supplementary Fig. 10b). In addition, the on-target activity of 10 was confirmed when the 
growth of (androgen-independent) 22Rv1 xenograft tumors was not influenced by treatment 
with 10 (Supplementary Fig. 11).
Discussion
While the majority of prostate cancers develop resistance to FDA-approved inhibitors of AR 
signaling, abundant clinical evidence suggests that in most CRPC, AR remains a viable 
target and is engaged in the regulation of processes of pathological importance. Thus, there 
is a significant unmet medical need for novel modulators of AR function for use in the 
treatment of hormone-refractory prostate cancer. The mechanisms underlying resistance to 
existing endocrine therapies include activation of secondary signaling cascades that increase 
AR activity, AR overexpression6, AR mutation4, and increased expression of constitutively 
active AR splice variants8–10. It is significant, therefore, that we have identified a class of 
compounds that act as competitive AR antagonists with a novel cyclobutane structure and 
unique activity profile. While these compounds are not effective against constitutively active 
AR variants that lack the ligand binding domain, 10 was found to inhibit full-length 
endogenous AR-regulated gene expression, slow PC cellular proliferation, and halt prostate 
tumor growth. More specifically, these CBs are of particular interest because they effectively 
inhibit AR in the context of receptor-overexpression and inhibit the activity of AR mutants 
that arise during enzalutamide (F876L), OHF (T877A), and Bic (W741C) treatment. 
Previously described discovery campaigns in this area have focused on the development of 
compounds that inhibit the T877A and W741C mutant receptors27–29 or on derivatives of 
enzalutamide that retain activity against the F876L mutant21,30. Our CBs, however, form a 
particularly promising class of antagonists that are structurally dissimilar to earlier 
generation AR antagonists and exhibit pan-mutant inhibitory activity.
Interestingly, some of the most potent CBs we have studied exhibit a 10 to 30-fold increased 
affinity and potency for the F876L AR over wild type receptor, suggesting the possibility for 
selective targeting of mutant AR signaling associated with previously treated hormone-
refractory prostate cancer. Mutant-selective AR inhibitors may provide effective therapy for 
hormone-refractory prostate cancer, while avoiding some of the negative side effects 
associated with androgen deprivation in other tissues (muscle and bone density loss, 
decreased libido, etc.). This approach has proven valuable in targeting the mutant form of 
BRAF, and in 2011, the FDA approved vemurafenib (PLX4032/RG7204, Plexxikon/Roche) 
for the treatment of metastatic melanoma bearing the BRAF V600E mutation31–33. It is 
anticipated that mutant-selective CBs, such as those described here, could provide a valuable 
basis for the development of therapeutics to treat advanced prostate cancer in a more 
effective and selective fashion.
The signature structural element of our AR antagonists is their cyclobutane core. While not 
unprecedented in medicinal compounds, cyclobutane-core structural components are 
relatively rare in both natural products and synthetic bioactive compounds. Most naturally 
occurring molecules in this class arise from sunlight-initiated [2+2] cycloaddition reactions 
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of stilbene or cinnamic acid-like precursors, leading to symmetric or quasi-symmetric tetra-
substituted cyclobutane dimers34–39. Coincidentally, examples of novel, synthetically-
derived bioactive cyclobutane-core compounds have also been isolated from the accidental 
photodimerization of drug candidates containing photo-active π-systems40,41. Despite their 
rarity, substituted cyclobutanes are intriguing as scaffolds for molecular probes and drug 
candidates due to their inherent three-dimensionality. In fact, molecules with a cyclobutane 
core have recently shown promise as agonists of glucagon-like peptide-1 (GLP-1) receptor 
in vitro and in vivo41,42. In addition, the conformational rigidity of the cyclobutane has been 
utilized in the development of peptidomimetic inhibitors of metallocarboxypeptidases43. Our 
work expands the utility of cyclobutane-containing molecules as novel AR inhibitors in 
models of CRPC. In particular, the capacity of 10 to inhibit agonist induced transcription 
and proliferation in LNCaP and VCaP cells, and the ability to inhibit AR in multiple models 
of CRPC, suggests that optimized cyclobutanes of this class may become practical 
therapeutics for hormone-refractory prostate cancer. The striking inhibition of both wt and 
F876L AR-containing tumors with 10 in murine models demonstrates that these compounds 
retain their activity in vivo, further supporting their position as viable medicinal candidates.
The structural uniqueness of the CBs translates to differences in their mechanism of action.. 
Similar to enzalutamide, the CBs reduce the recruitment of AR to gene-regulatory chromatin 
binding sites. However, in contrast to enzalutamide and other antiandrogens, the unique 
structure of the CBs stabilise a conformation in AR that is most similar to the apo-receptor. 
Hence, by binding to AR with minimal disruption in receptor structure, the CBs foster an 
AR:CB complex that remains bound to HSP90 in the cytoplasm, thereby inhibiting nuclear 
localization and recruitment to chromatin. This novel mechanism helps explain their notable 
anti-tumor activity in animal models of CRPC and suggests that 10 has the potential to be 
exploited as an AR antagonist with a distinctive mechanistic profile.
Online Methods
Reagents
R1881 and 3H-R1881 were purchased from Perkin Elmer. Enzalutamide, bicalutamide, and 
flutamide were purchased from Cayman Chemical Company (> 98% purity). Antibodies for 
AR (N-20, SC-27316, 1:10,000; 441, SC-7305, 1:10,000), α-tubulin (E-19, SC-27316, 
1:10,000), Topoisomerase 1 (C-21, SC-32736, 1:5,000), and HSP90 (F-8, SC-13119, 
1:1,000) were purchased from Santa Cruz Biotechnology. Antibody for β-actin (AC-15, 
A5441, 1:10,000) was purchased from Sigma. LNCaP, PC3, and 22rv1 cells were 
maintained in RPMI supplemented with 8% fetal bovine serum (FBS). VCAP, HEK293, and 
DU145 cells were maintained in DMEM (8% FBS) and LAPC4 cells were maintained in 
IMDM (15% FBS). All cell lines were obtained from ATCC which uses short tandem repeat 
(STR) DNA profiles for authentication. None of the cell lines used for these studies are 
listed in the database of commonly misidentified cell lines maintained by ICLAC. All cell 
lines tested negative for mycoplasma. Stable LNCaP cell lines expressing wt-AR (LNCaP-
AR), F876L mutation (LNCaP-F876L), or empty vector control (LNCaP-XIP) were 
generated using pQC-XIP retrovirus vector (Promega).
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Prostate Cancer Cell Proliferation Assay
Cells were plated in 96-well plates (10k cells/well) and treated with hormone for 7 days. 
Cellular proliferation was quantified by measuring DNA content using Hoechst dye1.
RNA Isolation and Real-Time PCR
LNCaP-XIP, LNCaP-AR, or LNCaP-F876L cells were seeded in 12-well plates in RPMI 
1640 (8% charcoal-stripped fetal calf serum (CFS)). After 48 hrs, cells were treated with 
ligand (18 hrs) and total RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad). 
AR target gene transcription was assessed by realtime PCR as described previously2. Data 
are normalized to the GAPDH housekeeping gene. For heatmaps, the data were first 
normalized to the vehicle control. Data were then standardized using the following equation, 
Z= X – μ/σ, where X is the normalized signal (zero centered), μ is the average signal for all 
conditions within a gene, and σ is the standard deviation (SD) for all conditions within a 
gene. The data were then clustered by the Ward hierarchical clustering method using JMP 
(SAS).
Chromatin Immunoprecipitation Assay
LNCaP-AR and LNCaP-F876L cells were plated in 150 mm dishes in RPMI 1640 (8% 
CFS). Following 48 hr incubation, cells were treated with ligand for 4 hr. 1% formaldehyde 
was added (10 min) and quenched with 250 mM glycine (5 min). Cells were washed twice 
with PBS, pelleted, lysed in RIPA buffer (50 mM Tris [pH 7.5], 0.15 M NaCl, 1% NP-40, 
0.5% Na-deoxycholate, 0.05% SDS, 1 mM EDTA), sonicated, and then processed for 
chromatin immunoprecipitation using either anti-AR (N-20) or IgG antibodies (Santa Cruz), 
as previously described44.
High Content Imaging
Cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100, 
and stained for AR (1:400, N-20, Santa Cruz) and counterstained for DNA (DAPI, Sigma) 
and F-actin (rhodamine Phalloidin, Thermo Fisher Scientific). Stained cells were imaged 
and analyzed with a Cellomics ArrayScan VTI HCS system. 20 fields per well of a 24-well 
plate were imaged at 20× magnification and analyzed using the Compartmental Analysis 
Bioapplication. First, images were collected by autofocusing on nuclear staining in channel 
1. Cells were then identified in channel 1, indicated as valid object count (VOC).
Nuclear:Cytoplasmic ratio of AR staining was determined by measuring channel 2 signal 
within the nuclear mask identified in channel 1 versus the cytoplasmic area, which was 
approximated by extending 2 pixels outside of the nuclear mask. Experiments were 
performed in triplicate and repeated five times.
AR Conformation Profiling Assay
HepG2 cells were maintained in Basal Medium Eagles (10% FBS). For mammalian two-
hybrid based AR cofactor profiling assays, cells were transfected with VP16-AR, 
5XGalLuc3, Gal4-interactor, and Renilla-Luciferase. Cells were induced with ligand (48 hr) 
and then dual luciferase assays were performed. Renilla luciferase served as control for 
cellular toxicity and transfection efficiency. The data was standardized to avoid bias due to 
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signal strength and clustered with the Ward hierarchical clustering method using JMP 
(SAS)22. The hierarchical cluster dendrogram was ordered by the first principal component.
Reporter Gene Assay
CV1 cells were seeded into 96-well cell culture plates and transfected with Lipofectin 
(Invitrogen) according to the manufacturer’s protocol. For AR transcriptional assays, the 
DNA mixture consisted of pcDNA-AR (wt or mutant), MMTV-Luc (reporter gene), and 
Renilla-Luc (for assessing transfection efficiency and toxicity). Following overnight 
incubation, cells were induced with hormone for 24 hrs. Cells were lysed and luciferase 
activity was quantified using Dual Luciferase Reagent (DLR).
Whole Cell Competition Binding Assay
HEK293 cells were transfected with vectors expressing wt-AR or AR mutants using 
FuGene6 (Promega) and 100,000 cells were plated in a 24-well plate (DMEM, 8% CFS) 
coated with 0.2% gelatin. Following overnight incubation, cells were treated with ligand in 
the presence of 0.1 nM 3H-R1881. To determine background levels of radioactivity, control 
wells were treated with 500X cold R1881 (50 nM). After 2 hr incubation, cells were lysed 
using 200 μl lysis buffer (2% SDS, 10% Glycerol, 10 mM Tris-HCl [pH 6.8]); then volumes 
were increased to 500 μl using 10 mM Tris-HCl (pH 8.0). 300 μl of the lysates were added 
to 3 mL of Cytoscint (MP Biomedicals) and analyzed by scintillation counting (Beckman LS 
6000SC). Lysate protein levels were quantified using the Pierce BCA Protein Assay Kit 
(Thermo Scientific) per the manufacturer’s instructions.
In-Cell Western Assay
LNCaP cells were plated in 96-well clear bottom black plates (20K cells/well) in RPMI 
supplemented with 8% CFS. Following 48 hr incubation, cells were treated with hormone 
for 18 hrs. Cells were fixed with formaldehyde (3.7%) and permeabilized using PBS (0.1% 
TRITON X-100). Cells were incubated with anti-AR antibody (N20, 1:2000), washed with 
PBS (0.1% Tween), and stained with 2nd antibody (Biotium CF770 goat anti-rabbit, 1:2000). 
AR protein expression was assessed using the LI-COR Odyssey imaging system. DRAQ5 
(DNA stain, 1:10,000, Thermo Scientific) was used to normalize AR protein expression.
Western Analysis
LNCaP cells were plated in RPMI supplemented with 8% CFS. Following 48 hr incubation, 
cells were treated with hormone for 18 hr. Cells were lysed (50 mM Tris, pH 7.5, 150 mM 
NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.05% SDS, 5 mM EDTA, 50 mM NaF, 15 mM 
Na-pyrophosphate, 10 mM β-glycerophosphate, 2 mM Na-orthovanadate, 1X protease 
inhibitor cocktail) and cleared whole cell extracts were analyzed by Bradford assay. 50 μg of 
protein per sample were resolved by SDS-PAGE (8%), transferred to nitrocellulose 
membrane, and analyzed by western blot using antibodies to AR (N-20, Santa Cruz) and β-
actin (Sigma) per manufacturer’s instructions.
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Cellular Fractionation Assay
HEK293 cells were transfected with wt-AR expression vector using FuGene6. Following 
overnight incubation, cells were treated for 4 hr with ligand in the absence and presence of 
R1881 (0.1 nM). Nuclear and cytoplasmic fractions were obtained using NE-PER reagent 
from Thermo Scientific (78835) according to manufacturers instructions. Proteins were 
subjected to SDS/PAGE and western blotting using AR (N-20, Santa Cruz), α-tubulin (E-19, 
Santa Cruz), and topoisomerase 1 (C-21, Santa Cruz) antibodies.
Co-Immunoprecipitation Assay
HEK293 cells were transfected with wt-AR expression vector using FuGene6. Following 
overnight incubation, cells were treated for 4 hr with ligand in the absence and presence of 
R1881 (0.1nM). Cells were lysed in immunoprecipitation (IP) buffer (20 mM Tris HCl pH 
7.5, 50 mM NaCl, 20 mM Na2MoO4, 0.5% Nonidet P-40 (NP-40), 1 mM EDTA, 1 mM 
EGTA (pH 8.0), 2 mM DTT, plus protease inhibitors) and incubated for 15 min at 4C. 
Lysates were pre-cleared with normal rabbit IgG (Santa Cruz) and Protein A/G Plus –
Agarose beads (Santa Cruz). Pre-cleared lysates (500 μg total protein) were incubated with 
10μg anti-AR antibody (N-20) or normal rabbit IgG overnight at 4C. 50 μl Protein A/G Plus 
– Agarose beads were added for 4 hr at 4C. Beads were washed 3X with IP buffer and
immunoprecipitated proteins were subjected to SDS/PAGE and western blotting using AR 
441 (gift from Dr. Dean Edwards, University of Colorado Heath Sciences Center) and 
HSP90 (F-8, Santa Cruz) antibodies.
Animal Studies
All procedures were approved by the Duke University Institutional Animal Care and Use 
Committee. LNCaP-F876L xenograft study: Male NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
mice were castrated at 6 weeks of age, 10 days prior to injection of 3 × 106 LNCaP-AR 
F876L cells sc into the flank. Tumor growth was measured 3x weekly by caliper (tumor 
volume = (A2 x B)/2, where A < B). When tumor volume reached ~0.1 cm3, mice were 
randomized (n = 12–14) to 28 days of daily i.p. injection with vehicle (10% DMSO, 30% 
PEG400, 60% corn oil), enz (15 mg/kg) or 10 (30–100 mg/kg). PK time course: 6-week old 
male NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were castrated 10 days prior to sc 
injection of 3 × 106 LNCaP-AR-F876L cells (1:1 with matrigel) into the flank. Tumor 
growth was measured 3x weekly by caliper (tumor volume = (A2 x B)/2, where A < B). 
When tumor volume reached ~1 cm3, 100 mg/kg 10 (vehicle formulation: DMSO:PEG 
400:corn oil, 1:3:6) was administered by i.p. injection. Animals (n = 3 per time point) were 
euthanized 10 min, 30 min, 1.5 hr, 3 hr, 8 hr, and 24 hr after injection, and blood and tissues 
were retained for analysis. LNCaP xenograft assay: 2.5 × 106 LNCaP cells (1:1 with 
matrigel) were injected sc into the flank of 6-week old male NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) mice. Tumor growth was measured 3x weekly by caliper (tumor volume = 
(A2 x B)/2, where A < B). When tumor volume reached ~0.1 cm3, mice were randomized (n 
= 9–15) to 28 days of daily i.p. injection with vehicle (as above), Enz (15 mg/kg) or 10 (5–
100 mg/kg). 8 additional mice were castrated and received daily vehicle treatment. 22RV1 
xenograft assay: 6 week old male NU/NU mice were castrated 10 days prior to injection of 1 
× 106 22RV1 cells sc and tumor measurement as above. When tumor volume reached 0.11–
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0.18 cm3, mice were randomized to 14 days of daily i.p. injection with vehicle (n = 4) or 10 
(100 mg/kg, n = 5) formulated as above. All Statistical analyses were performed using 
GraphPad Prism 6 and are described in the Statistics section below.
PK sample collection and processing—Blood was collected into heparinized 
polypropylene (PP) 1.5-mL tubes (10 μL of 1000 U/mL heparin for up to 0.5 mL blood) and 
plasma separated at 1300 g for 10 min at RT. All specimens were stored at −80 °C until the 
day of analysis. Tissue was homogenized with 2 parts water (w/v), either by rotary 
homogenizer (PTFE rotor/glass tube; liver) or by cryo-crushing under liquid nitrogen 
(stainless in-house made tool; tumor and muscle). Into 200-μL PP tube, 20 μL of either 
blood, plasma, or tissue homogenate and 40 μL of methanol/acetonitrile (1/1, v/v, containing 
2.5 μg/mL 10 deuterium labeled internal std.) was added and vigorously agitated in FastPrep 
vortexer (Thermo-Savant) at speed 4 for 20 sec. After centrifugation at 13,600 g for 5 min at 
RT, 5 μL of supernatant was mixed with 195 μL of mobile phase A/acetonitrile (1/1, v/v; see 
below) and 5 μL injected into LC/MS/MS system.
Liquid chromatography tandem-mass spectrometry (LC/MS/MS)—The analysis 
was performed on Shimadzu 20A series LC system coupled with Applied Biosciences/
SCIEX API 4000 QTrap MS/MS spectrometer. Column: Phenomenex, C18 4×3 mm guard 
cartridge (P/N AJ0-4287) and Agilent ZORBAX Eclipse Plus, C18 4.6×50 mm 1.8 μm 
particle size (P/N 959941-902) analytical column at 35 °C. Mobile phase solvents (all MS-
grade): A - 0.1% formic acid in water, 2% acetonitrile; B – acetonitrile. Elution gradient at 1 
mL/min: 0–1.5 min 30–95% B, 1.5–2.5 min 95% B, 2.5–2.7 min 95–30% B. Run time: 7 
min. MRM transitions for 10 and labeled 10 (m/z): 433.0/217.0 and 443.1/222, respectively. 
Positive-ion mode. DP: 66 V, EP: 10 V, ion-spray voltage: 5500 V, curtain gas: 30, ion-
source gas 1: 30, ion-source gas 2: 25. Lower limits of quantification (LLOQ) for plasma, 
blood, liver, muscle, and tumor were: 0.08, 0.16, 0.16, 0.08 and 0.08 μg/mL, respectively. 
Calibration curve samples (n=6) were prepared by adding increasing amounts of 10 to 
control matrix (plasma, blood, or tissue homogenate) obtained from non-treated animals.
Statistical Analyses
For in vitro studies, s.d. and s.e.m. are reported in figure legends for technical and biological 
replicates. Nuclear/cytoplasmic AR ratios as detected by Cellomics analysis (Figure 4) were 
subjected to one-way ANOVA comparison followed by Bonferroni multiple comparisons 
test. Statistically similar (p < 0.05) groups are indicated by letters a–d.
For LNCaP-AR-F876L xenograft study, using the sample size and power function in JMP 
statistical software (SAS Institute, Inc), it was estimated that a group size of N = 13 per 
treatment arm would be required to reliably detect a statistically relevant (p<0.05) 25% 
change with 80% confidence, given the anticipated 15% variability for the tumor models 
utilized in these studies (α = 0.05, st. dev. = 0.15, confidence of 0.8, s/delta of 0.25). This 
estimate is based on one way ANOVA followed by the Student Newman Keul’s test. This 
group size is in accordance with current literature in the field. Animals were randomized to 
treatment when tumor size measured 0.12–0.17 cm3 volume. Animals were allocated to 
treatment such that the initial tumor volume average per group was 0.15 +/− 0.015 cm3 
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volume. Group size for each treatment arm was as follows: Vehicle 14, Enzalutamide 14, 10 
30 mg/kg 14, 10 50 mg/kg 13, 10 100 mg/kg 13. One animal (10 100 mg/kg) died prior to 
the conclusion of the study and was therefore excluded from the presented data and from 
post-study statistical analyses. All other animals were included. The investigator and 
personnel were not blinded during this study. Average tumor volume and s.e.m. for each 
group over 28 days of dosing are presented in Figure 5c. These data were subjected to 
exponential growth curve analysis constrained to share an initial value, and to two-way 
ANOVA analysis followed by Bonferroni multiple comparison test. 10 50 mg/kg and 10 100 
mg/kg were found to significantly differ from the vehicle treated control (p<0.0001) on days 
14–28 of treatment. All other treatments were statistically similar to the vehicle control 
throughout the study. Groups showed equivalent variance (10–15% with normal distribution) 
throughout all time points, justifying the statistical analyses that were selected.
For LNCaP xenograft study, using the sample size and power function in JMP statistical 
software (SAS Institute, Inc) it was estimated that an intended group size of 14 per treatment 
arm would be required to reliably detect with 80% confidence a statistically relevant 
(p<0.05) change of 30% given the anticipated 15% variability for the tumor models utilized 
in these studies (α=.05, st dev = 0.15, confidence of 0.8, s/delta of 0.3). For those groups in 
which 35% or greater change was anticipated (i.e. castrate), fewer animals were anticipated 
to be required, and the groups were weighted accordingly. These estimates were based on 
one way ANOVA followed by the Student Newman Keul’s test. This group size is in 
accordance with current literature in the field. Animals were randomized to treatment when 
tumor size measured 0.1–0.2 cm3 volume. Animals were allocated to treatment such that the 
initial tumor volume average per group was 0.15 +/− 0.02 cm3 volume. Group size for each 
treatment arm was as follows: Vehicle 15, Enzalutamide 15, 10 5 mg/kg 13, 10 15 mg/kg 13, 
10 50 mg/kg 10, 10 100 mg/kg 10, castrate 8. One animal (10 50 mg/kg) died prior to the 
conclusion of the study and was therefore excluded from the presented data and from post-
study statistical analyses. All other animals were included. The investigator and personnel 
were not blinded during these studies. Survival curve analysis was used to detect significant 
difference in days to reach 0.5 cm3 volume, an endpoint arbitrarily selected prior to initiating 
the study. All treatments resulted in a significant delay in time to endpoint as compared to 
the vehicle control, as determined by Logrank (Mantel-Cox) test.
For the 22RV1 xenograft study, JMP analysis (α = 0.05, st. dev. = 0.10, confidence of 0.8, s/
delta of 0.4) advised the use of 5 animals per treatment arm. Group size for each treatment 
arm contained 5 animals. One vehicle treated animal died prior to the conclusion of the 
study and was excluded from the statistical analyses. Average tumor volume and S.E.M. for 
each group over 14 days of dosing are presented in Supplementary Fig. 11. These data were 
subjected to exponential growth curve analysis constrained to share an initial value, and to 
two-way ANOVA analysis followed by Bonferroni multiple comparison test. No significant 
difference was detected between these treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CBs compete with androgen binding to AR
HEK293 cells were transfected with vectors expressing (a) wt-AR (b) F876L (c) T877A or 
(d) W741C and duplicate wells were incubated for 2 hours with 3H-R1881 plus increasing 
doses of 1, 10, and 15. Scintillation counting was used to measure bound R1881 and total 
protein was used to normalize cell number. Experiment was performed in triplicate and a 
representative experiment is shown.
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Figure 2. CBs inhibit AR activity in models of CRPC
(a) LNCaP cells were treated with vehicle, R1881 (0.1 nM), Enz (5 μM) + R1881 (0.1 nM), 
or 10 (5 μM) + R1881 (0.1 nM). Real-time PCR was used to assess AR target gene 
expression. Error bars represent s.d. of triplicate wells from a representative experiment 
performed in triplicate. (b) LNCaP cells were treated with R1881 (0.1 nM) and increasing 
concentrations of Enz or 10. Cell growth was determined after 7 days by measuring DNA 
content using Hoechst dye. Error bars represent s.d. of triplicate wells from a representative 
experiment performed in triplicate. Real-time PCR analysis was used to assess AR target 
gene expression in LNCaP-AR cells treated with 1, 10, 15 (20 μM), Enz (10 μM), or Bic (10 
μM) in the (c) absence or (d) presence of R1881 (0.1 nM). Heatmaps were generated from 
real-time PCR data after analysis with JMP pro software (SAS) using the Ward hierarchical 
clustering algorithm. Experiments were performed in duplicate and a representative 
experiment is shown (e) and (f) same as in (c) and (d) except for activity in LNCaP-F876L 
cells was measured.
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Figure 3. CBs are mechanistically distinct antiandrogens
(a) 1, 10, and 15 induce a novel conformation in AR. Interaction profiles of AR ligands and 
vehicle control (veh) were generated using 29 AR cofactors. Profiles were analyzed using 
Ward hierarchical clustering and the resulting dendogram and heatmap represent the 
structural relationships between the seven clusters (agonists and partial agonists, blue and 
orange; CPA and RU 486, light blue and purple; enzalutamide and related structures, green; 
antagonists with partial agonist activity, grey; apo, red). (b and c) 10 inhibits binding of AR 
to DNA in models of CRPC. LNCaP-AR (b) or LNCaP-F876L (c) cells were treated with 
Enz (10 μM), Bic (10 μM), or 10 (20 μM) in the absence or presence of R1881 (LNCaP-AR, 
0.1 nM; LNCaP-F876L, 0.3 nM) and chromatin immunoprecipitation was performed to 
assess the recruitment of AR to target gene promoters by real-time PCR. Error bars in b and 
c represent s.d. of triplicate wells from a representative experiment performed in duplicate.
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Figure 4. 10 inhibits nuclear localization of AR
(a–c) 10 does not promote nuclear accumulation of AR. (a) VCaP cells (top) or HEK293 
cells transfected with a vector expressing wt-AR (bottom) were treated with R1881 (0.1 
nM), Enz (20 μM), or 10 (20 μM) as indicated. Cells were stained for AR, DAPI, and 
Phalloidin and N/C ratios were quantified using high content imaging (ArrayScan). Error 
bars represent s.e.m. from 5 independent experiments. Letters indicate statistically similar 
groups (p < 0.05) as determined by one-way ANOVA analysis followed by Bonferroni 
multiple comparison test. (b) Representative fluorescence microscopy images from an 
ArrayScan experiment with VCaP cells after indicated treatments; AR (green), DAPI (blue), 
and Phalloidin (red). (c) HEK293 cells expressing wt-AR were treated with indicated 
ligands for 4 hours prior to fractionation into nuclear and cytoplasmic compartments. 
Proteins were analyzed by infrared fluorescent imaging (LI-COR Odyssey) and AR levels 
were normalized to α-tubulin (cytoplasm) or topoisomerase (nucleus) and presented as 
percent relative to vehicle treatment. The experiment was performed in triplicate and a 
representative experiment is shown. Full gels in Supplementary Fig. 12. (d) 10 does not 
disrupt the interaction between HSP90 and AR. HEK293 cells were transfected with wt-AR 
expression vector and treated with the indicated ligands for 4 hours prior to 
immunoprecipitation using antiAR antibody. Immunoprecipitated proteins were assessed by 
western blotting using AR and HSP90 antibodies. The experiment was performed in 
triplicate and a representative experiment is shown. Full gels in Supplementary Fig. 12.
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Figure 5. 10 does not promote cell growth in models of CRPC and inhibits tumor growth in a 
model of enzalutamide resistance
(a) LNCaP-AR or (b) LNCaP-F876L cells were treated for 7 days with increasing doses of 
Enz, Bic, or 10 and cell growth was assessed by measuring DNA content. Error bars indicate 
s.d. of triplicate samples from a representative experiment performed in duplicate. (c) 
LNCaP-F876L cells were implanted into the flank of castrated male NSG mice. When 
tumors reached ~0.1 cm3 volume (4–5 weeks post-injection), mice (n = 13–14) were 
randomized to vehicle, Enz (15 mg/kg – MTD by this administration route), or 10 (30, 50, or 
100 mg/kg). Tumor growth for each group is presented as average tumor volume +/− s.e.m. 
per study arm (N= 13 or 14) during 28 daily treatments. Only 50 and 100 mg/kg 10 arms 
differ significantly from the vehicle control in days 14–28 of treatment (2-way ANOVA 
followed by Bonferroni comparison, * p < 0.0001).
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